Organon & Co. (NYSE:OGN) Trading 5.7% Higher – Still a Buy?

Shares of Organon & Co. (NYSE:OGN) shot up 5.7% during trading on Tuesday . The company traded as high as $15.95 and last traded at $15.95. 1,984,320 shares changed hands during mid-day trading, a decline of 29% from the average session volume of 2,811,156 shares. The stock had previously closed at $15.08.

Analyst Upgrades and Downgrades

A number of research firms recently commented on OGN. TD Cowen upgraded Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Morgan Stanley dropped their price target on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, February 14th. Finally, Barclays cut their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $20.80.

Organon & Co. Price Performance

The stock has a market capitalization of $4.11 billion, a P/E ratio of 4.79, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The business has a fifty day simple moving average of $15.37 and a 200 day simple moving average of $17.22. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.57 billion. On average, analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Shareholders of record on Monday, February 24th will be issued a dividend of $0.28 per share. The ex-dividend date is Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.02%. Organon & Co.’s payout ratio is 33.63%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of OGN. Prospera Private Wealth LLC purchased a new position in Organon & Co. in the third quarter worth $25,000. Horizon Bancorp Inc. IN raised its holdings in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after buying an additional 1,585 shares during the last quarter. Millstone Evans Group LLC purchased a new position in Organon & Co. during the 4th quarter valued at about $29,000. Larson Financial Group LLC raised its holdings in shares of Organon & Co. by 345.4% during the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock valued at $33,000 after acquiring an additional 1,734 shares in the last quarter. Finally, Riverview Trust Co lifted its position in shares of Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock worth $36,000 after purchasing an additional 1,292 shares during the period. 77.43% of the stock is owned by institutional investors.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.